NeOnc Technologies IR

Welcome to the official Investor Relations profile of NeOnc Technologies (NASDAQ: NTHI).

[NeOnc Technologies IR @NeOncIR]

Institutional awareness of $NTHI continued to grow in May with 2 analyst firms initiating coverage:
🔹 Maxim Group: Buy | $20 Price Target
🔹 BTIG: Buy | $15 Price Target
Learn more about our latest announcements and Investor Relations updates at https://t.co/5gJdKbOPNV.

[NeOnc Technologies IR @NeOncIR]

$NTHI May demonstrated continued progress across multiple areas of the business, including clinical development, regulatory preparation, financial management, & growing awareness.

Explore latest company news & insights in our IR section: https://t.co/8adz33l5W5

[NeOnc Technologies IR @NeOncIR]

ICYMI: NeOnc Reports Tumor Remission Data & Advances Brain Cancer Treatment Platform $NTHI

https://t.co/qNmMtqY5AC

[NeOnc Technologies IR @NeOncIR]

We appreciate seeing thoughtful discussion on Reddit and across the broader biotech investor community surrounding NeOnc Technologies and the Company’s NEO100 clinical program.
$NTHI #Biotech #Glioblastoma #BrainCancer
https://t.co/tesylm6FFO

[NeOnc Technologies IR @NeOncIR]

NeOnc Technologies Holdings, Inc. ($NTHI) received new analyst coverage from Maxim Group, which initiated coverage with a Buy rating and a $20 price target.

Read more here: https://t.co/W2MQg1C3Wr

[NeOnc Technologies IR @NeOncIR]

NeOnc Technologies (Nasdaq: $NTHI) is proud to share Q1 2026 financial results and provide a business update highlighting continued progress across both of our clinical-stage CNS oncology programs.

Read the full announcement here: https://t.co/WMlsyvnA2i

[NeOnc Technologies IR @NeOncIR]

A quote from Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President of NeOnc Technologies, following the Company’s recent announcement regarding continued insider buying and a $500K+ personal investment ahead of upcoming NEO100 Phase 2a data catalysts. $NTHI

[NeOnc Technologies IR @NeOncIR]

$NTHI is proud to announce that CEO, Executive Chairman, & President Amir Heshmatpour has invested more than $500K in recent weeks and nearly $1M over the past year. All purchases were made with personal funds & disclosed through SEC Form 4 filings.
https://t.co/8MHgBMDJgM

[NeOnc Technologies IR @NeOncIR]

@Parkk_Claire (2/2) NeOnc’s therapeutic approach is centered on improving CNS penetration & enabling treatment candidates to reach tumor tissue better.
We believe continued progress in targeted delivery technologies may help expand treatment possibilities for patients facing brain tumors.

[NeOnc Technologies IR @NeOncIR]

@Parkk_Claire (1/2) Thank you for highlighting one of the most significant challenges in neuro-oncology.
The blood-brain barrier continues to limit the effectiveness of many conventional therapies in aggressive brain cancers, making drug delivery a critical area of innovation.

[NeOnc Technologies IR @NeOncIR]

@JodieRosss (2/2) NeOnc’s development strategy is built around improving CNS delivery & enabling therapeutics to reach the tumor environment.
We believe advances in both treatment mechanisms & delivery approaches will be critical to improving outcomes for patients with brain tumors.

[NeOnc Technologies IR @NeOncIR]

@JodieRosss (1/2) As research continues to reinforce the role of tumor metabolism and targeted therapeutics in aggressive brain cancers, overcoming the blood-brain barrier remains one of the field’s central challenges.

[NeOnc Technologies IR @NeOncIR]

NeOnc Technologies continues to gain momentum.
BTIG has initiated coverage with a Buy rating and a $15 PT, led by analyst Thomas Shrader.

A strong vote of confidence as we advance innovative therapies for CNS cancers.

$NTHI #Biotech #BTIG #BuyRating

https://t.co/EUKQB0bzdG

[NeOnc Technologies IR @NeOncIR]

NeOnc recently announced approximately $300K in insider purchases of $NTHI stock by its Chairman and CEO, while providing added context on 2025 financial results.

A strong vote of confidence that aligns leadership with long-term shareholder value.

https://t.co/nlEtQJdkX5

[NeOnc Technologies IR @NeOncIR]

NeOnc Technologies $NTHI recently announced approximately $300,000 in open-market stock purchases by Chairman & CEO Amir Heshmatpour, reinforcing management’s alignment with shareholders and confidence in the Company’s long-term strategy.

https://t.co/nlEtQJdSMD

[NeOnc Technologies IR @NeOncIR]

ICYMI, Watch on YouTube: NeOnc Technologies | One Year on NASDAQ $NTHI | Progress, Pipeline & What’s Next
One year after NeOnc's listing on NASDAQ, NeOnc reflects on key clinical and regulatory milestones achieved as a public company.
https://t.co/dyoyVyMr39

[NeOnc Technologies IR @NeOncIR]

Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President of #NeOncTechnologies $NTHI, commented on the recent Business Update and Q4 2025 Financial Report:

[NeOnc Technologies IR @NeOncIR]

NeOnc Technologies recently reported Q4 2025 results and highlights of clinical and strategic progress, reflecting continued execution across clinical development, leadership expansion, and strategic positioning heading into the next phase of growth. $NTHI
https://t.co/BN319eeYcv

[NeOnc Technologies IR @NeOncIR]

We’re thrilled to celebrate our CEO, Amir Heshmatpour, being featured in USA Today’s list of Top Entrepreneurs Going Into 2026, a testament to visionary leadership and bold innovation shaping the future of biotech.

#Leadership #Entrepreneurship #Biotech

https://t.co/cmGOoAd8Qt

[NeOnc Technologies IR @NeOncIR]

Driving Scientific Innovation into Commercial Impact

$NTHI leverages a robust ecosystem of research, regulatory, and management expertise to accelerate the translation of cutting-edge science from the lab to the clinic and into the marketplace.

https://t.co/5R9AKL2Rh2